8,810 Shares in MetLife, Inc. $MET Acquired by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds LLC acquired 8,810 shares of MetLife, Inc., valued at approximately $708,000, as part of its second-quarter portfolio filings.
• MetLife's stock saw an increase of 2.4%, with a market capitalization of $53.91 billion and a PE ratio of 13.74.
• The company recently announced a quarterly dividend of $0.5675 per share, which represents an annualized yield of 2.8% and a payout ratio of 38.47%.

Counterpoint Mutual Funds LLC acquired a new position in shares of MetLife, Inc. (NYSE:MET - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,810 shares of the financial services provider's stock, valued at approximately $708,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. McGlone Suttner Wealth Management Inc. increased its position in MetLife by 4.4% during the 2nd quarter. McGlone Suttner Wealth Management Inc. now owns 19,387 shares of the financial services provider's stock worth $1,559,000 after purchasing an additional 809 shares in the last quarter. GAMMA Investing LLC increased its position in MetLife by 14.3% during the 2nd quarter. GAMMA Investing LLC now owns 11,612 shares of the financial services provider's stock worth $934,000 after purchasing an additional 1,450 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its position in MetLife by 1.9% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 9,128 shares of the financial services provider's stock worth $734,000 after purchasing an additional 166 shares in the last quarter. Farmers & Merchants Investments Inc. increased its position in MetLife by 0.8% during the 2nd quarter. Farmers & Merchants Investments Inc. now owns 211,398 shares of the financial services provider's stock worth $17,001,000 after purchasing an additional 1,672 shares in the last quarter. Finally, Abound Wealth Management increased its position in MetLife by 652.3% during the 2nd quarter. Abound Wealth Management now owns 489 shares of the financial services provider's stock worth $39,000 after purchasing an additional 424 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

MetLife Stock Up 2.4%

Shares of NYSE MET opened at $81.07 on Tuesday. The firm has a market cap of $53.91 billion, a PE ratio of 13.74, a P/E/G ratio of 0.71 and a beta of 0.87. MetLife, Inc. has a 12-month low of $65.21 and a 12-month high of $89.05. The company's fifty day simple moving average is $78.37 and its 200 day simple moving average is $78.08. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.57.

MetLife (NYSE:MET - Get Free Report) last issued its earnings results on Wednesday, August 6th. The financial services provider reported $2.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.32 by ($0.30). The company had revenue of $17.34 billion for the quarter, compared to the consensus estimate of $18.58 billion. MetLife had a return on equity of 19.88% and a net margin of 5.83%.The firm's revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.28 earnings per share. As a group, sell-side analysts forecast that MetLife, Inc. will post 9.65 earnings per share for the current fiscal year.

MetLife Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 5th were paid a dividend of $0.5675 per share. The ex-dividend date of this dividend was Tuesday, August 5th. This represents a $2.27 annualized dividend and a yield of 2.8%. MetLife's dividend payout ratio is currently 38.47%.

Analyst Ratings Changes

A number of research firms recently issued reports on MET. JPMorgan Chase & Co. upped their price objective on shares of MetLife from $86.00 to $95.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 8th. UBS Group reduced their target price on shares of MetLife from $94.00 to $91.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Morgan Stanley reduced their target price on shares of MetLife from $98.00 to $94.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. Cowen reissued a "buy" rating on shares of MetLife in a report on Friday, August 22nd. Finally, Jefferies Financial Group boosted their target price on shares of MetLife from $100.00 to $103.00 and gave the stock a "buy" rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $94.64.

About MetLife

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.

Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.